MyFinsight
Home
Blog
About
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
8141.59%
Quick Ratio
8141.59%
Cash Ratio
569.89%
Debt to Asset Ratio
5.58%
Unit: Thousand (K) dollars
Assets Breakdown
Receivable from genevant license
Investments in marketable short-...
Cash and cash equivalents
Others
Liabilities Breakdown
Issued and outstanding 197,634,1...
Deficit
Additional paid-in capital
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
19,171
23,706
18,008
22,408
Investments in marketable securities, current
-
-
73,463
-
Investments in marketable short-term securities
73,454
71,520
-
71,294
Accounts receivable
369
1,312
1,447
905
Receivable from genevant license
179,373
178,741
-
-
Prepaid expenses and other current assets
1,516
1,732
1,538
2,835
Total current assets
273,883
277,011
94,456
97,442
Property and equipment, net of accumulated depreciation and impairment of 235 (december 31, 2025 213)
10
22
32
137
Right of use asset
-
-
0
0
Other non-current assets
132
131
130
131
Total assets
274,025
277,164
94,618
97,710
Accounts payable and accrued liabilities
2,850
4,474
5,459
4,653
Deferred license revenue, current
-
-
0
0
Lease liability, current
514
631
547
531
Total current liabilities
3,364
5,105
6,006
5,184
Liability related to sale of future royalties
3,111
3,278
3,442
3,684
Deferred license revenue, non-current
-
-
0
0
Contingent consideration
8,817
8,604
8,395
11,052
Lease liability, non-current
0
0
199
391
Total liabilities
15,292
16,987
18,042
20,311
Issued and outstanding 197,634,118 (december 31, 2025 192,531,225)
1,448,177
1,444,494
1,421,429
1,418,560
Additional paid-in capital
74,321
74,256
83,318
83,285
Deficit
-1,215,521
-1,210,378
-1,380,073
-1,376,317
Accumulated other comprehensive loss
-48,244
-48,195
-48,098
-48,129
Total stockholders equity
258,733
260,177
76,576
77,399
Total liabilities and stockholders equity
274,025
277,164
94,618
97,710
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Receivable from genevant
license
$179,373K
Investments in marketable
short-term securities
$73,454K
(21.06%↑ Y/Y)
Cash and cash
equivalents
$19,171K
(-48.76%↓ Y/Y)
Prepaid expenses and
other current assets
$1,516K
(-62.16%↓ Y/Y)
Accounts receivable
$369K
(-64.00%↓ Y/Y)
Total current assets
$273,883K
(165.60%↑ Y/Y)
Other non-current
assets
$132K
Property and equipment,
net of accumulated...
$10K
(-93.24%↓ Y/Y)
Total assets
$274,025K
(165.36%↑ Y/Y)
Total liabilities and
stockholders equity
$274,025K
(165.36%↑ Y/Y)
Total stockholders
equity
$258,733K
(211.82%↑ Y/Y)
Total liabilities
$15,292K
(-24.64%↓ Y/Y)
Deficit
-$1,215,521K
(11.18%↑ Y/Y)
Accumulated other
comprehensive loss
-$48,244K
(-0.12%↓ Y/Y)
Issued and outstanding
197,634,118 (december 31,...
$1,448,177K
(2.19%↑ Y/Y)
Contingent consideration
$8,817K
(-18.24%↓ Y/Y)
Total current
liabilities
$3,364K
(-33.01%↓ Y/Y)
Liability related to sale
of future...
$3,111K
(-20.43%↓ Y/Y)
Additional paid-in capital
$74,321K
(-10.05%↓ Y/Y)
Accounts payable and
accrued liabilities
$2,850K
(-36.78%↓ Y/Y)
Lease liability,
current
$514K
(0.00%↑ Y/Y)
Buy us a coffee